Technical advances offer new potential to TK1 as a tumor biomarker
A recently published review paper highlights TK1 as a tumor biomarker
Among other advantages the authors summarize that
- the immunoassay of TK1 makes it a more sensitive biomarker for studying solid malignancies, thereby increasing its value as a biomarker
- TK1 levels in malignancies are associated with clinical stage, offering potential for patient and subject stratification
- Elevated and/or increasing serum TK1 levels after treatment indicate therapy escape
Authors are Kiran Kumar Jagarlamudi and Martin Shaw.
Read more here